Movement disorders, a common problem in children with neurologic impairment, are receiving increasing clinical attention. The differences in movement disorders between adults and children are striking; presentation is frequently insidious and may be characterized by mild hypotonia. The clinical manifestations of extrapyramidal disorders are profoundly influenced by the age of onset. The conditions reviewed in this article are expressed clinically by the occurrence of abnormalities of movement and posture, often in association with disturbances of muscle tone. This article reviews empiric drug use and recommendations for childhood movement disorders. (J Child Neurol 2003;18:S40—S49).
Get full access to this article
View all access options for this article.
References
1.
Jankovic J.: Phenomenology and classification of tics. Neurol Clin North Am1997;15:267—275.
2.
Hagberg G., Zetterstrom R.: Decreasing perinatal mortality. Increase in cerebral palsy morbidity. Acta Paediatr Scand1989;78:664—670.
3.
Aicardi J., Bax M.: Cerebral palsy, in Aicardi J (ed): Diseases of the Nervous System in Childhood, 2nd ed. London, MacKeith Press, 1998,210-239.
4.
Polani PE: The natural history of choreoathetoid cerebral palsy. Guy Hosp Rep1959;108—132.
5.
Burke RE, Fahn S., Gold AP: Delayed-onset dystonia in patients with “static” encephalopathy . J Neurol Neurosurg Psychiatry1980;43:93—104.
6.
Young AB, Penney JB: Biochemical and functional organization of the basal ganglia, in Jankovic J, Tolosa E (eds): Parkinson's Disease and Movement Disorders, 3rd ed. Baltimore, Williams and Wilkins , 1998, 1—13.
7.
Cavada C., Goldman-Rakic PS: Topographic segregation of corticostriatal projection from posterior parietal subdivisions in the macaque monkey. Neuroscience1991;42:683—696.
8.
Alexander GE , Crutcher MD: Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci1990;13:266—271.
9.
Carpenter MB , Whittier JR, Mettler FA: Analysis of choreoid hyperkinesias in the rhesus monkey. Surgical and pharmacological analysis of hyperkinesias resulting from lesions in the subthalamic nucleus of Lys. J Comp Neurol1950;92:293—332.
10.
Green LN: Corticosteroids in the treatment of Syndenham's chorea. Arch Neurol1978;35—53.
11.
Blunt SB, Brooks DJ, Kennard C.: Steroid-responsive chorea in childhood following cardiac transplantation. Mov Disord1994;9: 112—113.
12.
Jankovic J. , Beach J.: Long term effects of tetrabenazine in hyperkinetic movement disorders. Neurology1997;48:358—362.
13.
Daoud AS, Zaki M., Shakir R., et al: Effectiveness of sodium valproate in the treatment of Sydenham's chorea. Neurology1990;40: 1140—1141.
14.
Sethi KD, Patel BP: Inconsistent response to divalproex sodium in hemichorea/hemiballism. Neurology1990;40:1630—1631.
15.
Hallett M., Toro C.: Dystonia and the supplementary sensorimotor area. Adv Neurol1996; 70: 471—476.
16.
Lang AE: High dose anticholinergic therapy in adult dystonia. Can J Neurol Sci1986;13:42—46.
17.
Brans JW, Lindeboom R., Snoek JW, et al: Botulinum toxin versus trihexphenidyl in cervical dystonia: A prospective randomized, double-blind controlled trial. Neurology1996;46:1066—1072.
18.
Greene O., Shale H., Fahn S.: Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord1988;3:46—60.
19.
Jankovic J.: Treatment of hyperkinetic movement disorders with tetrabenazine: A double-blind crossover study. Ann Neurol1982;11: 41—47.
20.
Marsden CD, Marion MH, Quinn N.: The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry1984;47:1166—1173.
21.
Weiner WJ, Lang AE (eds): Movement Disorders. A Comprehensive Survey. Mount Kisko, NY, Futura, 1989.
22.
Green P., Fahn S.: Baclofen in the treatment of idiopathic dystonia in children. Mov Disord1992;7:48—52.
Singer HS, Hahn IH, Moran TH: Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann Neurol1991;30:558—562.
27.
Leckman JE, Detlar J., Harcherik DF, et al: Short and long-term treatment of Tourette's syndrome with clonidine. A clinical perspective. Neurology1985;35:343—351.
28.
Walkup JT, Scahill LD, Riddle MA: Disruptive behavior, hyperactivity, and learning disabilities in children with Tourette's syndrome, in Weiner WJ, Lang AE (eds): Advances in Neurology. Behavioural Neurology of Movement Disorders, vol. 65. New York, Raven Press, 1995, 259—272.
29.
Erenberg G. , Cruse RP, Rothner AD: The natural history of Tourette syndrome. A follow-up study. Ann Neurol1987;22:383—385.
30.
Chappell PB , Leckman JF, Riddle MA: The pharmacologic treatment of the tic disorders. ChildAdolesc Psychiatr Clin North Am1995 ;4:197—216.
Van der Linden C., Bruggerman R., Van Woerkom TC: Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: An open pilot dose titration study with risperidone . Mov Disord1994;9: 687—688.
33.
Sallee FR, Kurlan R., Goetz CG, et al: Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. J Am Acad Child Adolesc Psychiatry2000;39:292—299.
34.
Gilbert DL, Sethuraman G., Sine L., et al: Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology2000 ;54:1310—1315.
35.
Jankovic J. , Beech J.: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology1997;48:358—362.
36.
Obeso JA, Artieda J., Rothwell JC, et al: The treatment of severe action myoclonus. Brain1989;112:765—777.
37.
Obeso JA, Arteida J., Quinn NP, et al: Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol1988;11: 529—536.
38.
Krauss GL, Bergin A., Kramer RE, et al: Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology2001;56:411—412.
39.
Kyllerman M. , Ben-Menachem E.: Zonisamide for progressive myoclonus epilepsy: Long-term observations in seven patients. Epilepsy Res1998;29:109—114.
40.
Pranzatelli MR: The pharmacology of myoclonus. Clin Neuropharmacol1995;8:99—130.
41.
Chokroverty S., Manocha MK, Duvoisin RC: A physiologic and pharmacologic study in anticholinergic-responsive essential myoclonus. Neurology1987;37:608—615.
42.
Elble RJ: Central mechanisms of tremor. J Clin Neurophysiol1996; 13:133—144.
43.
Koller WC, Royse VL: Efficacy of primidone in essential tremor. Neurology1986;36:121—124.
44.
Sasso E., Perucca E., Fava R., et al: Quantitative comparison of barbiturates in essential hand and head tremor. Mov Disord1991;6: 304—309.
45.
Conner GS: A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology2002;59:132—134.
46.
Burns RS, Chiueh CC, Markey SP, et al: A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4 phenyl-1,2,3,6-tetrahydropyridine . Proc Natl Acad Sci U S A1983;80: 4546—4550.
47.
Bergman H., Wichmann T., De Long MR: Reversal of experimental parkinsonism by lesions of the subthalamic nucleus . Science1990;249:1436—1438.
48.
Botez MI, Botez-Marquard T., Elie R., et al: Amantidine hydrochloride in heredodegenerative ataxia: A double blind study. J Neurol Neurosurg Psychiatry1996;61:259—264.
49.
Botez MI, Young SN, Rotez T., et al: Treatment of heredo-degenerative ataxias with amantadine hydrochloride . Can J Neurol Sci1991;18:307—311.
50.
Milla PJ, Jackson Adm: A controlled trial of baclofen in children with cerebral palsy. J Int Med Res1977;5:398—404.
51.
Young RR, Enure M., Nance PW, et al: Current issues in spasticity management. Neurologist1997;3:261—275.
Nogen AG: Effect of dantrolene sodium on the incidence of seizures in children with spasticity. ChildsBrain1979;5:420—425.
54.
Nance PW, Young RR: Antispasmodic medications. Phys Med Rehabil Clin North Am1999;10:337—355.
55.
Ford F., Bleck EE, Aptekar RG, et al: Efficacy of dantrolene sodium in the treatment of spastic cerebral palsy. Dev Med Child Neurol1976;18:770—783.
56.
Denhoff E., Feldman S., Smith MG, et al: Treatment of spastic cerebral-palsied children with dantrolene sodium. Dev Med Child Neurol1975;17:736—742.
57.
Halsam Rha, Walcher JR, Leitman PS, et al: Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil1974;55:384—388.
58.
Gracies J-M. , Nance P., Elovic E., et al: Traditional pharmacologic treatments for spasticity part II: General and regional treatments. Muscle Nerve1997;20(Suppl 6):S92—S120.
59.
Cutter NC, Scott DD, Johnson JC, Whiteneck G.: Gabapentin effect on spasticity in muliple sclerosis. A placebo controlled randomized trial. Arch Phys Med Rehabil2000 ;81:164—169.
